PureTech Health PLC - Boston-based biotechnology company - Says LYT-100 trial shows around 50% improvement in gastrointestinal and central nervous system related adverse events in adults suffering from idiopathic pulmonary fibrosis compared to US Food & Drug Administration-approved pirfenidone. Adds data shows higher dose of LYT-100 well-tolerated with no additional incidence of GI or CNS AEs when titrated up from 550 milligrams dosage.
Chief Medical Officer Julie Krop says: "These data highlight the potential for LYT-100 to improve both the treatment experience for people with IPF and - most importantly - enable them to stay on treatment longer and at an efficacious dose, which should improve their clinical outcome. Our goal with the ELEVATE IPF trial is to validate the ability of LYT-100 to deliver a more tolerable treatment with equivalent efficacy to pirfenidone at one dose while also exploring the potential for enhanced efficacy at a higher dose."
Current stock price: 185.20 pence, down 0.9% in London on Wednesday afternoon
12-month change: down 14%
By Sabrina Penty, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
PureTech (PRTC)